Synthetic peptide antigens representing the repeat sequences of malarial antigens showed poor immunogenicity and protection in clinical trials. In the present study, RESA, an asexual blood stage antigen, containing (EENVEHDA) 2 and (DDEHVEEPTVA) 2 sequences were chemically linked to a promiscous T-cell determinant (CS.T3) of the circumsporozoite protein of P.falciparum. The synthetic constructs either alone or coentrapped with immunoadjuvants (nor muramyl dipeptide\lauroyl tetrapeptide) were admini- stered in liposomes to mice of varying genetic background and the immunogenicity of different formulations were compared under identical experimental conditions. The RESA peptide formulations containing the T-cell determinant and the adjuvants generated high titre and affinity antibodies in all the strains, as compared to peptide(s) alone. The booster immunization induced a strong anamnestic response in each group. Though the major IgG isotype is of IgG 1 and IgG 2 b interestingly, formulations containing CS.T3 have a higher proportion of cytophilic IgG 2 b isotype. There was a significant fall in the levels of IgG 2 b isotype while IgG 1 levels were maintained same in the third bleed (day 60, without booster immunization). The mixed peptide group preparation containing the adjuvant is found to be a better immunogen than that of respective peptides itself. The in vitro merozoite reinvasion inhibition assay showed 76-96% inhibition with the formulations containing RESA peptide(s)-CS.T3 and the adjuvant, while with peptides alone the inhibition was 50-56%. This study highlights the importance of an alternative approach for developing peptide based immunogen against malaria.